Showing 685 news articles about New & experimental HIV treatments

Filters Content type: Editors' picks Topic: New & experimental HIV treatments

News and information about clinical trials and regulatory approval of new medications to treat HIV.

New & experimental HIV treatments

Phase 3 DOR/ISL Shows Promise for HIV Treatment

Editor's pick
Infectious Disease Special Edition
31 December 2025
New & experimental HIV treatments

Gilead’s Investigational Single-Tablet Regimen of Bictegravir and Lenacapavir for HIV Treatment Meets Primary Endpoint in Phase 3 ARTISTRY-2 Trial

Editor's pick
Gilead Sciences press release
16 December 2025
Government, leadership & policy

Top 10 HIV Clinical Developments of 2025

Editor's pick
TheBodyPro
15 December 2025
New & experimental HIV treatments

Lenacapavir drug resistance in phase 1b study

Editor's pick
i-Base
25 November 2025
New & experimental HIV treatments

Merck's HIV combo matches Gilead's Biktarvy in latest phase 3 test for islatravir

Editor's pick
FierceBiotech
22 November 2025
New & experimental HIV treatments

Gilead hails phase 3 victory for single-tablet combo of bictegravir and lenacapavir, preps filings

Editor's pick
FiercePharma
17 November 2025
New & experimental HIV treatments

IDWeek 2025: Pirmitegravir demonstrates proof of concept in HIV

Editor's pick
Clinical Trials Arena
30 October 2025
New & experimental HIV treatments

Weekly Oral HIV Treatment Looks Good at Two Years

Editor's pick
POZ
23 October 2025
New & experimental HIV treatments

HIV Maturation Inhibitor Shows Promise in Early Study

Editor's pick
POZ
4 September 2025
New & experimental HIV treatments

Ulonivirine Shows Promise for Weekly Oral HIV Treatment

Editor's pick
POZ
4 August 2025
New & experimental HIV treatments

U.S. FDA Accepts New Drug Application for Merck’s Doravirine/Islatravir, an Investigational, Once-Daily, Oral, Two-Drug Regimen for Treatment of Adults with Virologically Suppressed HIV-1 Infection

Editor's pick
Merck press release
10 July 2025
New & experimental HIV treatments

FDA Pauses Trials of Two Experimental Long-Acting HIV Drugs

Editor's pick
POZ
12 June 2025
New & experimental HIV treatments

ACTG Presents Study at CROI Demonstrating Potential of CMV-specific Antiviral Inhibitor to Improve Aging-Related Outcomes among People Living with HIV and CMV

Editor's pick
GlobeNewswire
18 March 2025
New & experimental HIV treatments

Drug candidate may 'unmask' latent HIV-infected cells, mark them for destruction

Editor's pick
Medical Xpress
20 March 2024
New & experimental HIV treatments

New Once-Daily HIV Oral Alternative Advances

Editor's pick
Medscape (requires free registration)
9 March 2024
New & experimental HIV treatments

CytoDyn finally clears FDA hold on HIV program after 2 years

Editor's pick
FierceBiotech
8 March 2024
New & experimental HIV treatments

CytoDyn announces submission of revised HIV clinical trial protocol to FDA

Editor's pick
CytoDyn press release
6 February 2024
New & experimental HIV treatments

Lenacapavir May Be Beneficial for Individuals Infected With HIV-2

Editor's pick
Infectious Disease Advisor
29 January 2024
New & experimental HIV treatments

Calibr announces license agreement with Gilead to develop a long-acting HIV antiviral agent for treatment in combination with lenacapavir

Editor's pick
EurekAlert!
8 January 2024
New & experimental HIV treatments

Trogarzo [Ibalizumab] Label Updated With 90-Second IV Push Loading Dose

Editor's pick
Infectious Disease Advisor
20 December 2023
Treatment simplification strategies

DTG/3TC vs TDF/FTC dual therapy: ALTAR study results too limited and too early to comment

Editor's pick
i-Base
6 December 2023
People with limited treatment options

Intramuscular Administration of HIV Treatment Ibalizumab Compared With IV Infusion

Editor's pick
Monthly Prescribing Reference
17 October 2023
Pharmaceutical industry

People with HIV offered hope of self-injected drug at home

Editor's pick
The Guardian
3 October 2023
Injectable & long-acting HIV treatment

Could this new hydrogel make HIV therapy more convenient?

Editor's pick
EurekAlert!
28 September 2023